What is the role of interleukin-10 in ischemia-reperfusion injury?

Body of text: I/R injury of the small intestine is consequently a critical problem that is important. DHP-PMX therapy can remove circulating endotoxins and reduce various cytokines, even in patients with high levels of plasma cytokines. DHP-PMX therapy has also been attempted for severe sepsis secondary to intra-abdominal infection, acute lung injury, and acute respiratory distress syndrome caused by sepsis, and its effectiveness has been reported.

A research article to be published on September 21, 2008 in the World Journal of Gastroenterology addresses this question. The research team led by Prof. Izumi Takeyoshi from Gunma University Graduate School of Medicine in Japan hypothesized that DHP-PMX therapy could reduce I/R injury and demonstrated the usefulness of this therapy on pulmonary warm I/R injury in a canine model.

The Authors suggested that the absorption of anandamide by PMX might abolish the diverse negative effects of anandamide such as hypotension, immunosuppression, and cytotoxicity. Taking these results into consideration, the possibility exists that treatment with PMX not only removes endotoxin, but also reduces inflammatory reactions through the inhibition of various inflammatory cascades and has an effective role on I/R injury.

They demonstrated that direct hemoperfusion with a polymyxin B-immobilized cartridge reduced the reperfusion injury in small intestine. DHP-PMX therapy reduced warm I/R injury of the small intestine, and IL-10 may play a role to inhibit I/R injury with DHP-PMX therapy. This study was nicely designed and performed.

Reference: Sato H, Oshima K, Arakawa K, Kobayashi K, Yamazaki H, Suto Y, Takeyoshi I. Direct hemoperfusion with a polymyxin B-immobilized cartridge in intestinal warm ischemia reperfusion.World J Gastroenterol 2008; 14(35): 5436-5441
http://www.wjgnet.com/1007-9327/14/5436.asp

Correspondence to: Izumi Takeyoshi, MD, Professor, Chairman, Department of Thoracic and Visceral Organ Surgery, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebashi, Gunma 371-8511,Japan takeyosi@showa.gunma-u.ac.jp
Telephone: +81-27-2208245 Fax: +81-27-2208255

World Journal of Gastroenterology (WJG), a leading international journal in gastroenterology and hepatology, has established a reputation for publishing first class research on esophageal cancer, gastric cancer, liver cancer, viral hepatitis, colorectal cancer, and H pylori infection and provides a forum for both clinicians and scientists. WJG has been indexed and abstracted in Current Contents/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch) and Journal Citation Reports/Science Edition, Index Medicus, MEDLINE and PubMed, Chemical Abstracts, EMBASE/Excerpta Medica, Abstracts Journals, Nature Clinical Practice Gastroenterology and Hepatology, CAB Abstracts and Global Health. ISI JCR 2003-2000 IF: 3.318, 2.532, 1.445 and 0.993. WJG is a weekly journal published by WJG Press. The publication dates are the 7th, 14th, 21st, and 28th day of every month. WJG is supported by The National Natural Science Foundation of China, No. 30224801 and No. 30424812, and was founded with the name of China National Journal of New Gastroenterology on October 1, 1995, and renamed WJG on January 25, 1998.

The WJG Press mainly publishes World Journal of Gastroenterology.